Financial Statements and Auditors' Report
C Square Healthcare Private Limited
31 March 2024

C Square Healthcare Private Limited			
Balance Sheet as at 31 March 2024			(Amount in ₹ Lakhs)
		As at	As at
CONTRIBUTION AND LIABILITIES	Note	31-Mar-2024	31-Mar-2023
Shareholder's fund			
Equity share capital	3	224.14	224.10
Reserves and surplus	4	(1,849.49)	(1,224.51)
W	_	(1,625.35)	(1,000.41)
Non-current liabilities			
Long-term borrowings	5	5,928.78	6,725.54
Long-term provisions	6	44.14	7.75
Other Non-current liabilities	7	48.76	49.26
W I SHE THERED	_	6,021.68	6,782.55
Current liabilities			
Short-term borrowings	8	1,490.18	1,170.10
Trade payables	9		
Total outstanding dues of micro enterprises and small enterprises		120.47	110.39
Total outstanding dues of creditors other than micro enterprises and small enterprises		926.44	781.92
Other current liabilities	10	615.58	431.17
Short-term provisions	6	2.13	20.62
	-	3,154.80	2,514.20
Total	1	7,551.12	8,296.34
ASSETS	-	1,001.12	0,230.34
Non-current assets			
Property, plant and equipment (and Intangible assets)			
- Property, plant and equiptment	11	6,450.36	6,798.99
- Intangible assets	11	7.99	10.18
- Capital work in progress	12	233.60	233.60
Long-term loans and advances	13	265.73	263.72
		6,957.68	7,306.49
Current assets	<del></del>		.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Inventories	14	98.80	105.02
Trade receivables	15	86.21	109.88
Cash and bank balances	16	20.25	279.35
Short term loans and advances	17	356.01	426.37
Other current assets	18	32,17	69,23
5	50°580		

Background, Basis of Preparation and Summary of significant accounting policies

The accompanying notes are an integral part of the financial statements. This is the Balance Sheet referred to in our report of even date.

For GVNKA & Assocaites

Chartered Accountants

Firm Registration Number: 023904N

per Prashanth Vellanki

**Partner** 

Total

UDIN: 24226413B1<GEEK4964

Bengaluru

06-Sep-24

For and on behalf of Board of Directors

593.44

7,551.12

C Square Healthcare Private Limited

CIN: U85191KA2013PTC070244

Ramachandra Prakash Bharathura

**Managing Director** 

DIN: 06780998

Bengaluru 06-Sep-24

989.85

8,296.34

Srinivas Chirukuri

Director

QIN: 03531032

BENGALURU Bengaluru 06-Sep-24

Statement of Profit and Loss for the year Income:	Note	For the Period 31-Mar-2024	(Amount in ₹ Lakhs) For the Period 31-Mar-2023
Revenue from operations	19	5,288.52	4,511.56
Other income	20	33,29	30.19
Total Income		5,321.81	4,541.76
Expenses:			
Purchase of medical consumable and drugs	21	911.17	825.54
Changes in inventories of medical consumable and drugs	22	6.22	26.15
Employee benefits expense	23	1,040.08	904.36
Finance costs	24	957.74	989.38
Depreciation and amortization expense	25	442.99	488.84
Other expenses	26	2,588.59	2,233.11
Total expenses		5,946.79	5,467.38
Profit/ (Loss) Before Exceptional, Prior Period, Extraordinary Items and Tax		(624.98)	(925.63)
Exceptional Items	27	-	245.86
Prior Period Items	28	-	1,582.66
Profit/ (Loss) Before Extraordinary Items and Tax		(624.98)	(2,754.14)
Extraordinary Items		•	
Profit/ (Loss) Before Tax (5-6)		(624.98)	(2,754.14)
Tax expense:			
Current tax			-
Deferred tax charge/ (benefit)		-	(211.43)
Total Tax Expense			(211.43)
Profit after tax (7-8)		(624.98)	(2,542.71)
Earnings/(Loss) per equity share (in ₹)			
(a) Basic		(27.89)	(113.46)
(b) Diluted		NA	NA
Background, Basis of Preparation and Summary of significant accounting policies	1&2		

The accompanying notes are an integral part of the financial statements. This is the Profit and Loss referred to in our report of even date.

For GVNKA & Assocaites

**Chartered Accountants** 

Firm Registration Number: 023904N

per Prashanth Vellanki

**Partner** 

Membership Number: 226413 UDIN: 24226413BKGEEK4964

Bengaluru

06-Sep-24

For and on behalf of Board of Directors

C Square Healthcare Private Limited

CIN: U85191KA2013PTC070244

Ramachandra Prakash Bharathura

**Managing Director** 

DIN: 06780998

Bengaluru 06-Sep-24 Srinivas Chirukuri

Director

DIN: 03531032

BENGALURU Bengaluru 06-Sep-24

560 073.

Cash Flow Statement for the year ended 31 Marc	ch 2024	(Amount in ₹ Lakhs)
	For the Year Ended 31-Mar-2024	For the Year Ended 31-Mar-2023
A. Cash Flow from Operating activities	specialization and the same	
Profit before tax	(624.98)	(2,754.14)
Adjustments to reconcile profits to cash	-	
generated by operating activities	440.00	
Depreciation and amortization expenses  Exceptional item - Bad debts	442.99	488.84
Provisions no longer required written back	:-	248.48
Prior period interest on finance lease	-	(2.62)
Prior period depreciation on assets under finance lease		2,456.27 615.48
Prior period - Reversal of rental expense		(1,493.77)
Prior period - Adjustment of depreciation	) <u>-</u>	4.68
Interest expenses	957.74	989.43
Interest (income)	(10.10)	(13.77)
Operating profit/(loss) before working capital changes	765.65	538.88
Changes in working capital; -	7,00,00	
Increase / (decrease) in trade payables	154.60	64.37
Increase / (decrease) in Other Current liabilities	(324.38)	82.34
Increase / (decrease) in Other Non Current liabilities	(0.50)	
Increase / (decrease) in Short term provisions	(18.49)	20.43
Increase / (decrease) in Long term provisions	36.39	(11.69)
Decrease / (increase) in trade receivables	23.67	95.16
Decrease / (increase) in inventories	6.22	26.15
Decrease / (increase) in Long-term loans & advances	(2.01)	(5.31)
Decrease / (increase) in Short term loans and advances	70.36	(19.70)
Decrease / (increase) in other current assets	37.32	(59.07)
Cash generated from /(used in) operations	748.83	731.57
Income tax paid (net of refund received)		141.88
Net cash flows from /(used in) operating activities (A)	748.83	589.68
B. Cash flow from Investing activities		
Purchase of Property, Plant and Equipment, including movement in CWIP and capital advances	(92.18)	(110.02)
Investments in bank deposits (other than cash equivalents)	256.27	(126.44)
Interest received on fixed deposits	9.84	13.15
Net cash flow from /(used in) investing activities (B)	173.93	(223.31)
C. Cash flow from Financing activities		
Share capital raised	=	0.71
Proceeds towards from Securities Premium	-	24.28
Movement in OD Balance	190.46	50.59
Proceeds of loans from Banks/ Financial institutions	507.30	874.33
Repayment of borrowings from Banks/ Financial institutions	(580.80)	(680.40)
Proceeds of loans from others	-	199.50
Repayment of loans from others	(216.65)	(146.46)
Repayment of finance lease obligation	(376.94)	(307.34)
Interest paid	(448.95)	(482.97)
Net cash flow from /(used in) financing activities (C)	(925.58)	(467.76)
Net increase / (decrease) in cash and cash equivalents (A+B+C)	(2.83)	(101.39)
Cash and cash equivalents at the beginning of the year	16.62	118.01
Cash and cash equivalents at the end of the year	13.79	16.62
ENT. TOTAL		0 1

Cash Flow Statement for the year ended 31 March 2024

(Amount in ₹ Lakhs)

	For the Year Ended 31-Mar-2024	For the Year Ended 31-Mar-2023
Reconciliation of Cash and cash equivalents with		Continued
the Balance Sheet:		
Cash and bank balances as at the end of the year	20.25	279.35
Less: Bank balances not considered as Cash and cash equivalents as defined in AS 3 Cash Flow Statements	6.46	262.73
Net Cash and cash equivalents (as defined in AS 3 Cash Flow Statements) included in Note 15	13.79	16.62

The notes referred to above form an integral part of the financial statements. This is the Cash flow statement referredto in our report of even date

For GVNKA & Assocaites **Chartered Accountants** 

Firm Registration Number: 023904N

per Prashanth Vellanki

**Partner** 

Membership Number: 226413

UDIN: 24226413BKGGEEK4964

Bengaluru 06-Sep-24 For and on behalf of Board of Directors C Square Healthcare Private Limited

CIN: U85191KA2013PTC070244

Ramachandra Prakash Bharathura

**Managing Director** THCARE

DIN: 06780998

Bengaluru 06-Sep-24 Srinivas Chirukuri

Director

QIN: 03531032

BENGALURU Bengaluru 560 073. \$6-Sep-24

Notes forming part of the Financial Statements for the year Ended 31 March 2024

## 1 Background of the Company

C Square Healthcare Pvt Ltd was incorporated on 23 July 2013 under the Indian Companies Act, 1956. The Company is engaged in the business of Human healthcare Activities. The Hospital has got the permission from "Karnataka Private Medical Establishment Authority" effective from 19th April 2018.

## 2 Significant accounting policies:

## 2.1 Basis for preparation of financial statements:

The financial statements of the Company have been prepared in accordance with the Generally Accepted Accounting Principles in India (Indian GAAP) to comply with the Accounting Standards specified under Section 133 of the Companies Act, 2013 and the relevant provisions of the Companies Act, 2013 ("the Act"), as applicable. The financial statements have been prepared on accrual basis under the historical cost convention. The accounting policies adopted in the preparation of the financial statements are consistent with those followed in the previous year.

## **Operational Outlook**

The company during the year ended 31 March 2024, has positive cash flow from operations. Hence, The Company is confident that the net cash inflows from operating activities in conjunction with the available line of credit, its ability to raise further capital and working capital receipts and payment will provide sufficient liquidity to meet its financial obligation as they fall due for the following twelve months. Further, the Company is in the process of raising equity from strategic and other investors to ease the debt servicing burden on the Company. Hence, these financial statements have been prepared adopting the going concern assumption. The Company prepared its cash flow forecasts under various scenarios and has performed additional sensitivities on certain key assumptions. Based on such an analysis and assessment of its ability to raise additional capital, the Company continues to prepare its financial statements on a going concern basis.

## 2.2 Use of estimates:

The preparation of the financial statements in conformity with Indian GAAP requires the Management to make estimates and assumptions considered in the reported amounts of assets and liabilities (including contingent liabilities) and the reported income and expenses during the year. The Management believes that the estimates used in preparation of the financial statements are prudent and reasonable. Future results could differ due to these estimates and the differences between the actual results and the estimates are recognised in the periods in which the results are known / materialise.

## 2.3 Revenue recognition:

## a) Income from Services Rendered

Operating income including inpatient and outpatient services, laboratory/ clinical services, management fees from hospitals, management fees from laboratories and income from satellite management fees from hospitals, management fees from laboratories and income from satellitecenters are recognised as and when the services are rendered.

## b) Sale of pharmacy items

Revenue from sale of goods is recognised when all significant risks and rewards of ownwership of goods have been passed to the buyer usually on delivery of the goods.

- c) Interest income is recognised on accrual basis.
- d) Dividend income is accounted for when the right to receive it is established.





Notes forming part of the Financial Statements for the year Ended 31 March 2024

## 2.4 Fixed assets:

All fixed assets, are carried at cost less accumulated depreciation / amortisation and impairment losses, if any. The cost of fixed assets comprises its purchase price net of any trade discounts and rebates, any import duties and other taxes (other than those subsequently recoverable from the tax authorities), any directly attributable expenditure on making the asset ready for its intended use, other incidental expenses and interest on borrowings attributable to acquisition of qualifying fixed assets up to the date the asset is ready for its intended use.

## 2.5 Intangible assets:

Intangible assets acquired separately are carried at cost less accumulated amortisation and accumulated impairment losses. Cost of a non-monetary asset acquired in exchange of another non-monetary asset is measured at fair value. The Company amortizes computer software using the straight method over the period of 3 years.

Gains or losses arising from derecognition of an Intangible Asset are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognised in the Statement of Profit and Loss when the asset is derecognised.

The company's intangible assets comprises assets with finite useful life which are amortised on a straight-line basis over the period of their expected useful life.

## 2.6 Depreciation / Amortization:

Depreciation is provided under the written down method based on the useful lives prescribed under Schedule II of Companies Act 2013 which are reproduced below. For assets purchased during the year, depreciation is provided proportionately based on the number of days asset is put to use during the year.

Asset Category	Depreciation / Amortization ( Useful Life in Years)
Computers & Peripherals	3
Furniture and Fixtures	10
Office equipment	5
Medical Equipment's	13
Medical Instruments	13
Plant & Equipment's	13

Hospital building is depreciated over Straight Line Method for 30 Years.

The estimated useful life of the intangible assets and the amortisation period are reviewed at the end of each financial year and the amortisation period is revised to reflect the changed pattern, if any.

## 2.7 Impairment of assets:

The carrying values of assets / cash generating units at each balance sheet date are reviewed for impairment. If any indication of impairment exists, the recoverable amount of such assets is estimated and impairment is recognised, if the carrying amount of these assets exceeds their recoverable amount. The recoverable amount is the greater of the net selling price and their value in use. Value in use is arrived at by discounting the future cash flows to their present value based on an appropriate discount factor. When there is indication that an impairment loss recognised for an asset in earlier accounting periods no longer exists or may have decreased, such reversal of impairment loss is recognised in the Statement of Profit and Loss.





Notes forming part of the Financial Statements for the year Ended 31 March 2024

## 2.8 Employee benefits:

Employee benefits include provident fund, employee state insurance scheme, gratuity fund and compensated absences.

## Defined contribution plans

The Company's contribution to provident fund and employee state insurance scheme are considered as defined contribution plans and are recognised as an expense in the Statement of Profit and Loss of the year in which the employee has rendered services.

## Defined benefit plan

The company provides for retirement benefits in the form of Gratuity. Benefits payable to eligible employees of the company with respect to gratuity, a defined benefit plan is accounted for on the basis of an actuarial valuation made by an independent actuary as at the balance sheet date. In accordance with the Payment of Gratuity Act, 1972, the plan provides for lump sum payments to vested employees on retirement, death while in service or on termination of employment an amount equivalent to 15 days basic salary for each completed year of service. Vesting occurs upon completion of five years of service. The present value of such obligation is determined by the projected unit credit method and adjusted for past service cost and fair value of plan assets as at the balance sheet date through which the obligations are to be settled. The resultant actuarial gain or loss on change in present value of the defined benefit obligation or change in return of the plan assets is recognised as an income or expense in the Statement of Profit and Loss.

## 2.8 Inventories

Inventories comprise of finished goods(Trading goods)

Finished goods are valued at cost or net realisable value which ever is lower.

## 2.9 Foreign currency transactions:

Foreign exchange transactions are recorded at the exchange rates prevailing on the date of the transaction. Exchange difference arising on the settlement of monetary items at rates different from those at which they were initially recorded is recognized as income or expense in the Statement of Profit and Loss in the period in which they arise.

Outstanding foreign currency monetary items are restated at the year-end rates as applicable. The net loss or gain arising on restatement is adjusted to the Statement of Profit and Loss.





Notes forming part of the Financial Statements for the year Ended 31 March 2024

## 2.10 Income tax:

## Current tax

Current tax is the amount of tax payable on the taxable income for the year as determined in accordance with the applicable tax rates and the provisions of the Income-tax Act, 1961.

## Minimum Alternate Tax

MAT paid in accordance with the laws, which gives future economic benefits in the form of adjustment to future income tax liability, is considered as an asset if there is convincing evidence that the company will pay normal income tax. Accordingly, MAT is recognised as an asset in the Balance Sheet wen it is highly probable that future economic benefit associated with it will flow to the company.

## Deferred tax

Deferred tax is recognised on timing differences, being the differences between the taxable income and the accounting income that originate in one period and are capable of reversal in one or more subsequent periods. Deferred tax is measured using the tax rates and the tax laws enacted or substantively enacted as at the reporting date. Deferred tax liabilities are recognised for all timing differences. Deferred tax assets are recognised for timing differences of items other than unabsorbed depreciation and carry forward losses only to the extent that reasonable certainty exists that sufficient future taxable income will be available against which these can be realised. However, if there are unabsorbed depreciation and carry forward of losses and items relating to capital losses, deferred tax assets are recognised only if there is virtual certainty supported by convincing evidence that there will be sufficient future taxable income available to realise the assets. Deferred tax assets are reviewed at each balance sheet date for their realisability.

## 2.11 Provisions and contingencies:

A provision is recognised when the Company has a present obligation as a result of past events and it is probable that an outflow of resources will be required to settle the obligation in respect of which a reliable estimate can be made. Provisions (excluding retirement benefits) are not discounted to their present value and are determined based on the best estimate required to settle the obligation at the balance sheet date. These are reviewed at each balance sheet date and adjusted to reflect the current best estimates. Contingent liabilities are disclosed in the Notes. Contingent assets are not recognised in the financial statements.

## 2.13 Leases:

A lease is classified as an operating Lease, if it does not transfer substantially all the risks and rewards incidental to ownership. Lease rentals are charged to Statement of Profit and Loss on straight-line basis over the lease term, estimated by the management.

## Finance Leases

Finance leases, which effectively transfer to the Company substantially all the risks and benefits incidental to ownership of the leased item, are capitalized at the lower of the fair value and present value of the minimum lease payments at the inception of the lease term and disclosed as leased assets. Lease payments are apportioned between the finance charges and reduction of the lease liability based on the implicit rate of return. Finance charges are charged directly against income.

If there is no reasonable certainty that the Company will obtain the ownership by the end of the lease term, capitalized leased assets are depreciated over the shorter of the estimated useful life of the asset or the lease term.

## 2.14 Earnings per share:

The basic earnings per share is computed by dividing the net profit / (loss) attributable to equity shareholders for the year by the weighted average number of equity shares outstanding during the year. The number of shares used in computing diluted earnings per share comprises the weighted average shares considered for deriving basic earnings per share and also the weighted average number of equity shares that could have been issued on the conversion of all dilutive potential equity shares.





Notes forming part of the Financial Statements for the year Ended 31 March 2024

## 2.15 Operating cycle:

Based on the nature of the products/activities of the Company and the normal time between acquisition of assets and their realisation in cash or cash equivalents, the Company has determined its operating cycle as 12 months for the purpose of classification of its assets and liabilities as current and non-current.

## 2.16 Borrowing Costs

Borrowing cost relating to acquisition/construction of qualifying assets are capitalised until the time all the substantial activities necessary to prepare the qualifying assets for their intended use are complete. A qualifying asset is the one that necessarily takes substantial period of time to get ready for its intended use/ sale. All other borrowing cost not eligible for inventories/capitalisation are charged to revenue.





Notes forming part of the Financial Statements for the year Ended 31 March 2024

(Amount in ₹ Lakhs)

3 Shareholder's Contribution	31-Mar-2024	31-Mar-2023
Authorized Shares 3,500,000 Equity Shares of Rs. 10 Each	350	350
Issued, subscribed and fully paid up shares	,	330
2,240,969 Equity Shares of Rs. 10 Each	224.14	224.10
	224.14	224.10

## a. Reconciliation of the shares outstanding at the beginning and at the end of the reporting period

	31-Ma	ar-2024	31-Mar-2	2023
Equity Shares	No of Shares	(Amount in ₹ Lakhs)	No of Shares	(Amount in ₹ Lakhs)
Balance at the beginning of the year	22,40,969	224.10	22,33,826	223.38
Issued during the year	-	-	7,143	0.71
Outstanding at the end of the year	22,40,969	224.10	22,40,969	224.10

## b. Terms/rights attached to equity shares

The Company has only one class of equity shares having a par value of Rs.10 per share. Each holder of equity shares is entitled to one vote per share. The Company declares and pays dividend (if any) in Indian Rupees. The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting, except Interim dividend.

In the event of liquidation of the Company, the holders of equity shares will be entitled to receive remaining assets of the Company, after distribution of all preferential amounts, if any. The distribution will be in proportion to the number of equity shares held by the shareholders.

## c. Details of shareholders holding more than 5% shares in the Company

	31-Ma	r-2024	31-Mar-20	023
Equity Shares of Rs 10 Each	No of Shares	% holding	No of Shares	% holding
Dr Srinivas Chirukuri	1,23,912	5.53%	1,23,912	5.53%
Dr Kudingila Radha Madhava	1,22,566	5.47%	1,22,566	5.47%
Dr Prakash Ramachandra	1,17,499	5.24%	1,17,499	5.24%

As per records of the Company, including its register of shareholders/members and other declarations received from shareholders regarding beneficial interest, the above shareholding represents both legal and beneficial ownership of shares.





Notes forming part of the Financial Statements for the year Ended 31 March 2024

(Amount in ₹ Lakhs)

## d. Shares held by the promoters at the end of the year

	No of	Shares	% of change du	ring the year
Name of the Promoter	31-Mar-2024	31-Mar-2023	Number of Shares	% of change during the year
Dr Srinivas Chirukuri	1,23,912	1,23,912	-	0.00%
Dr Kudingila Radha Madhava	1,22,566	1,22,566	-	0.00%
Dr Prakash Ramachandra	1,17,499	1,17,499	-	0.00%
Dr Diwakara Chaluvaiah	1,11,374	1,11,374	-	0.00%
Dr Mangeria Chinnappa Uthappa	1,02,499	1,02,499	-	0.00%
Dr Somnath Chatterjee	91,666	91,666	-	0.00%
Dr Shivashankar Appaswamy	83,666	83,666	-1	0.00%
Dr Nagabhushan Seshadri	68,666	68,666	-	0.00%
Dr Ajay Kumar Ravi	66,666	66,666	-	0.00%
Dr Chandrasekhar Sreedhara Nittur	66,666	66,666	-	0.00%
Dr Mallikarjun Kodampur	66,666	66,666	=	0.00%
Dr Prabhu Tonne	66,666	66,666	-	0.00%
Total	10,88,512	10,88,512	•	0.00%

e. Aggregate number of bonus shares issued and shares issued for consideration other than cash during the period of five years immediately preceding the reporting date :

The Company has not issued any bonus shares nor has there been any buy back of shares during five years immediately preceding 31 March 2024.

## f. Shares reserved for issue under options

As on 31 March 2024, there are no options outstanding.

Reserves and surplus	31-Mar-2024	31-Mar-2023
Security Premium		
Opening Balance	3,788.84	3,764.56
(+) Additions for the period		24.28
Closing balance	3,788.84	3,788.85
Surplus/(deficit) in the Statement of Profit and Loss		
Opening balance	(5,013.35)	(2,470.64)
Add: Net Profit/ (Loss) for the year	(624.98)	(2,542.71)
Less: Transfer to Genral Reserve	-	-
Closing balance	(5,638.33)	(5,013.35)
Total	(1,849.49)	(1,224.51)
	Opening Balance (+) Additions for the period Closing balance Surplus/(deficit) in the Statement of Profit and Loss Opening balance Add: Net Profit/ (Loss) for the year Less: Transfer to Genral Reserve Closing balance	Security Premium Opening Balance 3,788.84  (+) Additions for the period  Closing balance 3,788.84  Surplus/(deficit) in the Statement of Profit and Loss  Opening balance (5,013.35) Add: Net Profit/ (Loss) for the year (624.98) Less: Transfer to Genral Reserve -  Closing balance (5,638.33)





C Square Healthcare Private Limited

Notes forming part of the Financial Statements for the year Ended 31 March 2024

(Amount in ₹ Lakhs)

	/- "	mount in a Lumino,
5 Long-term borrowings	31-Mar-2024	31-Mar-2023
Secured -Term loans		
From Banks (1)	2,092.90	2,515.58
From Financial Institutions (2)	78.57	202.15
Unsecured -Term loans		
From Banks	=	-
From Financial Institutions (3)	30.50	65.05
Unsecured -Term loans From Others	533.63	750.29
	2,735.60	3,533.07
Less: Current Maturities on Long Term Borrowings	(707.06)	(599.43)
	2,028.54	2,933.64
Long-Term Maturities of Finance Lease Obligation	3,900.24	3,791.90
Total	5,928.78	6,725.54





## (Amount in ₹ Lakhs)

# C Square Healthcare Private Limited

Notes forming part of the Financial Statements

## (1) Secured Term Loans From Banks

S.No	Name of the Bank	Amount Outstanding	Repayment & Other Terms	Nature of Security
-	Bank of Maharastra - Term Loan	842.01	Door to Door Tenure 120 Month w.e.f Oct 21 till Sept 31. Principal Repayment shall be made in 96 PED installments of Rs. 9.24 Lakhs each to be started from Oct 23.( after moratorium period of 24 months) ROI of RLLR + 3% + 0.5% (BSS), i.e 10.40% p.a.,	Pari-passu charge by way of hypothecation of plant and machinery and all other Movable assets of the company (both present and future) excluding equipment purchased Out of Vendor Financing.
7	Bank of Maharastra - GECL	89.17	24 Months Moratorium till May 2022 and repayment starts from 89.17 June 22. ROI of 7.5% Fixed	Additonal Charge on existing security and assets, created out of finance. Charge on the asstes financed under the scheme to be created within a period of 3 months from the date of disbursal (except for FITL)
, M	Bank of Maharastra - Additional GECL	74.06	Door to Door Tenure 60 Month w.e.f Oct 21 till Sept 26. Principal Repayment shall be made in 36 PED installments of Rs. 2,94,450 each to be started from Oct 23.( after moratorium period of 24 months)  ROI of RLLR + 2.35%, i.e 9.25% p.a.,	Additonal Charge on existing security and assets, created out of finance. Charge on the asstes financed under the scheme to be created within a period of 3 months from the date of disbursal (except for FITL)
4	Bank of Maharastra - FITL	151.48	Door to Door Tenure 48 Month w.e.f Oct 21 till Sept 25. Principal Repayment shall be made in 24 PED installments of Rs. 8,41,667 each to be started from Oct 23.( after moratorium period of 24 months) ROI of I Year MCLR, i.e 7.30% p.a.,	Additonal Charge on existing security and assets, created out of finance. Charge on the asstes financed under the scheme to be created within a period of 3 months from the date of disbursal (except for FITL)
2	Union Bank of India - Term Loan	690.38	Door to Door Tenure 120 Month with moratorium of 24 months. Principal Repayment starts from Oct 2023 with equal installments of Rs. 7,62,500. ROI of EBLR (6.80%) + 4.25% - 0.25% + 0.50% (CRP) , i.e 11.30% p.a.,	Pari-passu charge by way of hypothecation of plant and machinery and Fixed assets of the company (both present and future) excluding equipment purchased out of Vendor Financing.





## (Amount in ₹ Lakhs)

## C Square Healthcare Private Limited

Notes forming part of the Financial Statements

## (1) Secured Term Loans From Banks

Additional (Second) Charge on the existing securitic (primary and collateral) and assets created out of finance of Dr. Residential Plat in the name of Dr. Residential Flat in the name of Dr. Raylabhushan J. S. Residential Flat in the name of Dr. Raylabhushan S. Residential Flat in the name of Dr. Raylabhushan J. Residential Flat in the name of Dr. Raylabhushan J. Residential Flat in the name of Dr. Raylabhushan J. S. Residential Flat in the name of Dr. Raylabhushan J. Residential Flat in the name of Dr. Raylabhushan J. Residential Flat in the name of Dr. Raylabhushan J. Residential Flat in the name of Dr. Raylabhushan J. Residential Flat in the name of Dr. Raylabhushan J. Residential Flat in the name of Dr. Trakabhuishan J. Residential Flat in the name of Dr. Trakabhuishan J. Residential Flat in the name of Dr. Prakash J. Residential Vacant Land in the name of Dr. Prakash Rama Chandra Rama		L			
Door to Door Tenure 60 Month with moratorium of 24 months. Principal Repayment starts from Nov 2022 with equal installments of Rs. 5,59,912. ROI of EBLR (6.80%) + 1.00% or 7.50% p.a., Whichever is less	S.No Name of the Bank Outstar	Amo Outstaı	unt nding	Repayment & Other Terms	Nature of Security
Door to Door Tenure 60 Month with moratorium of 24 months. Principal Repayment starts from Nov 2022 with equal installments of Rs. 5,59,912. ROI of EBLR (6.80%) + 1.00% or 7.50% p.a., Whichever is less					Additional (Second) Charge on the existing securities (primary and collateral) and assets created out of finance
Door to Door Tenure 60 Month with moratorium of 24 months. Principal Repayment starts from Nov 2022 with equal installments of Rs. 5,59,912. ROI of EBLR (6.80%) + 1.00% or 7.50% p.a., Whichever is less					excluding equipments purchased out of vendor financing.
Door to Door Tenure 60 Month with moratorium of 24 months. Principal Repayment starts from Nov 2022 with equal installments of Rs. 5,59,912. ROI of EBLR (6.80%) + 1.00% or 7.50% p.a., Whichever is less					Collateral includes
Door to Door Tenure 60 Month with moratorium of 24 months. Principal Repayment starts from Nov 2022 with equal installments of Rs. 5,59,912. ROI of EBLR (6.80%) + 1.00% or 7.50% p.a., Whichever is less					1. Residential Vacant Site in the name of Dr.
Door to Door Tenure 60 Month with moratorium of 24 months. Principal Repayment starts from Nov 2022 with equal installments of Rs. 5,59,912. ROI of EBLR (6.80%) + 1.00% or 7.50% p.a., Whichever is less					Nagabhushan J S.
Door to Door Tenure 60 Month with moratorium of 24 months. Principal Repayment starts from Nov 2022 with equal installments of Rs. 5,59,912. ROI of EBLR (6.80%) + 1.00% or 7.50% p.a., Whichever is less					2. Residential Flat in the name of Dr. Ravish Hiriyannaiah
Door to Door Tenure 60 Month with moratorium of 24 months. Principal Repayment starts from Nov 2022 with equal installments of Rs. 5,59,912. ROI of EBLR (6.80%) + 1.00% or 7.50% p.a., Whichever is less					3. Residential Flat in the name of Smt. Sai Lakshmi
Principal Repayment starts from Nov 2022 with equal installments of Rs. 5,59,912. ROI of EBLR (6.80%) + 1.00% or 7.50% p.a., Whichever is less				The state of the s	4. Residential Flat in the name of Dr MC Uthappa
of Ks. 5,59,912. ROI of EBLR (6.80%) + 1.00% or 7.50% p.a., Whichever is less	Union Bank of India -		81,33	Door to Door Tenure of Month Mith Indiatorium of 24 months. Principal Repayment starts from Nov 2022 with equal installments	5. Residential land & Building in the name of Dr Srinivas CH
7. Residential Vacant Land in the name of Mrs. Priy Vasanth Raj. 8. Residential Vacant land in the name of Dr. Praka Rama Chandra 9. Residential Site in the name of Dr. Prakash Ramachandra 10. FD of Rs. 36 Lakhs with A/c No 60289265405 11. FD of Rs. 200 Lakhs - Proposed	GECL			of Ks. 5,59,912. ROI of EBLR (6.80%) + 1.00% or 7.50% p.a., Whichever is less	<ol><li>Residential Appartment in the name of Dr. TR Sree Lakshmi</li></ol>
Vasanth Raj.  8. Residential Vacant land in the name of Dr. Praka Rama Chandra  9. Residential Site in the name of Dr. Prakash Ramachandra  10. FD of Rs. 36 Lakhs with A/c No 60289265405  11. FD of Rs. 200 Lakhs - Proposed					7. Residential Vacant Land in the name of Mrs. Priya
8. Residential Vacant land in the name of Dr. Praka Rama Chandra 9. Residential Site in the name of Dr. Prakash Ramachandra 10. FD of Rs. 36 Lakhs with A/c No 60289265405 11. FD of Rs. 200 Lakhs - Proposed				20	Vasanth Raj.
Rama Chandra 9. Residential Site in the name of Dr. Prakash Ramachandra 10. FD of Rs. 36 Lakhs with A/c No 60289265405 11. FD of Rs. 200 Lakhs - Proposed					8. Residential Vacant land in the name of Dr. Prakash
9. Residential Site in the name of Dr. Prakash Ramachandra 10. FD of Rs. 36 Lakhs with A/c No 60289265405 11. FD of Rs. 200 Lakhs - Proposed					Rama Chandra
Ramachandra 10. FD of Rs. 36 Lakhs with A/c No 60289265405 11. FD of Rs. 200 Lakhs - Proposed					9. Residential Site in the name of Dr. Prakash
10. FD of Rs. 36 Lakhs with A/c No 60289265405 11. FD of Rs. 200 Lakhs - Proposed					Ramachandra
11. FD of Rs. 200 Lakhs - Proposed					10. FD of Rs. 36 Lakhs with A/c No 60289265405
					11. FD of Rs. 200 Lakhs - Proposed







Notes forming part of the Financial Statements

(Amount in ₹ Lakhs)

## (1) Secured Term Loans From Banks

S.No	Name of the Bank	Amount Outstanding	Repayment & Other Terms	Nature of Security
	Union Bank of India - Additional GECL	100.93	Door to Door Tenure 60 Month with moratorium of 24 months. Principal Repayment with equal installments of Rs. 2,80,000. ROI of EBLR (6.80%) + 1.00% or 7.50% p.a., Whichever is less	Additional (Second) Charge on the existing securities (primary and collateral) and assets created out of finance excluding equipments purchased out of vendor financing. Collateral includes  1. Residential Vacant Site in the name of Dr.  Nagabhushan J S.  2. Residential Flat in the name of Dr. Ravish Hiriyannaiah  3. Residential Flat in the name of Dr. Ravish Hiriyannaiah  4. Residential Flat in the name of Dr. Ravish Hiriyannaiah  5. Residential Flat in the name of Dr. Ravishmi  6. Residential Appartment in the name of Dr. TR Sree  Lakshmi  7. Residential Vacant Land in the name of Dr. Prakash  8. Residential Vacant land in the name of Dr. Prakash  Rama Chandra  9. Residential Site in the name of Dr. Prakash  Ramachandra  10. FD of Rs. 36 Lakhs with Ac No 60289265405  11. FD of Rs. 200 Lakhs - Proposed

This space has been intentionally left blank

Continued.....





## (Amount in ₹ Lakhs)

# C Square Healthcare Private Limited

# Notes forming part of the Financial Statements

## (1) Secured Term Loans From Banks

S.No	Name of the Bank	Amount Outstanding	Repayment & Other Terms	Nature of Security
ω	Union Bank of India - FITL	48.10	Additional (Second) Charge on the existing securities (primary and collateral) and assets created out of finance excluding equipments purchased out of vendor financing Collateral includes 1. Residential Flat in the name of Dr. Ravish Hiryannaial Sresidential Flat in the name of Dr. Ravish Hiryannaial Sresidential Flat in the name of Dr. Ravish Hiryannaial Sresidential Flat in the name of Dr. Ravish Hiryannaial Sresidential Flat in the name of Dr. Ravish Hiryannaial Sresidential Flat in the name of Dr. Ravish Hiryannaial Sresidential Flat in the name of Dr. Ravish Hiryannaial Sresidential I and & Building in the name of Dr. Srinivas CH Rol of EBLR (6.80%) + 4.25% - 0.25% + 0.10% (CRP) , i.e  10.90% p.a.,  Rol of EBLR (6.80%) + 4.25% - 0.25% + 0.10% (CRP) , i.e Lakshmi 7. Residential Jacant Land in the name of Dr. Prakash Vasanth Raj. 8. Residential Vacant Land in the name of Dr. Prakash Rama Chandra 9. Residential Site in the name of Dr. Prakash Rama Chandra 10. FD of Rs. 36 Lakhs with Ac No 60289265405 11. FD of Rs. 200 Lakhs - Proposed	Additional (Second) Charge on the existing securities (primary and collateral) and assets created out of finance excluding equipments purchased out of vendor financing. Collateral includes  1. Residential Vacant Site in the name of Dr. Nagabhushan J S.  2. Residential Flat in the name of Dr. Ravish Hiriyannaiah S. Residential Flat in the name of Dr. Mc Uthappa 5. Residential Flat in the name of Dr. Mc Uthappa 6. Residential Islat in the name of Dr. Mc Uthappa 7. Residential Appartment in the name of Dr. TR Sree Lakshmi 7. Residential Vacant Land in the name of Dr. Prakash Vasanth Raj.  8. Residential Vacant land in the name of Dr. Prakash Rama Chandra  9. Residential Site in the name of Dr. Prakash Ramachandra  10. FD of Rs. 36 Lakhs with Alc No 60289265405
		The same of the sa		



Notes forming part of the Financial Statements

## (1) Secured Term Loans From Banks

S.No	o Name of the Bank	Amount Outstanding	Repayment & Other Terms	Nature of Security
თ	HDFC Bank	6.01	Repayable in 60 EMI from the date of drawdown with an 6.01 Installment amount of Rs.22.577.	Hypothecation of specific vehicle purchased
10	10 Kotak Mahindra Bank	9.43	Repayable in 24 EMI from the date of drawdown with an Installment amount of Rs.9,46,150 from May 2022. ROI of 12.5% P.a.	Current and Future Credit Card receivables of all outlet of the borrower firm.
	Total	2,092.90		





Notes forming part of the Financial Statements

# (2) Secured Term Loans From Financial Institutions

(Amount in ₹ Lakhs)

		Section (Section 1) and the section of the section		
S.N o	N Name of Financial Institution	Amount Outstanding	Repayment & Other Terms	Nature of Security
~	Clix Finance India Pvt Ltd		Repayable in 48 EMI from the date of drawdown with an 0.06 Installment amount of Rs.85,649. ROI of 13.00% P.a.	<ol> <li>First and Exclusive charge on the equipment financed by the lender.</li> <li>Security over collateral given by the borrower under or pursuant to any other facility granted by the lender and/ or its affiliates.</li> <li>Unconditional and Irrevocable personal guarantee of Dr. Prakash Rama Chandra, Dr. KR Madhava, Dr. MC Uthappa and C Srinivas.</li> </ol>
7	Bajaj Finance Limited	31.47	ROI of 10.50% P.a.	
n	De lage Landen Financial Services Pvt Ltd		Repayable in 66 Months with 6 months principal moratorium for 1. Dr. Prakash Ramacha 1. Dr. Prakash Ramacha New Equipment. 60 Months with 6 months principal moratorium for 2. Dr. Srinivas Chirukuri. 3. Dr. M C Uthappa. ROI is 12% Per Annum 4. Dr. K R Madhava (Promoter directors with	Personal Guarantors by: 1. Dr. Prakash Ramachandra, 2. Dr. Srinivas Chirukuri. 3. Dr. M C Uthappa. 4. Dr. K R Madhava (Promoter directors with 20% shareholding)
	Total	78.57		

This space is intentionally left blank.



Notes forming part of the Financial Statements

# (3) UnSecured Term Loans From Financial Institutions

S.N Name o In	Name of Financial Institution is Finance Ltd	Amount Outstanding	Repayment & Other Terms
	ince Ltd		
1 Axis Finance Ltd		8.46	Repayable in 12 EMI from the date of drawdown with an Installment amount of Rs.2,72,193. 8.46 ROI of 16.00% P.a.
2 NeoGrow	NeoGrowth Credit Pvt Ltd	10.90	Repayable in 900 daily installments from the date of drawdown with an Installment amount of Rs.5,837 per day.  10.90 Interest on the loan as annualized percentage rate (APR) is 19.74% calculated at monthly rest.
3 U Grow C	U Grow Capital Ltd	11.16	Repayable in 36 EMI from the date of drawdown with an Installment amount of Rs.93,271. ROI of 19.00% P.a.
	Total	30.50	

(4) UnSecured Term Loans From Others includes loans recceived from directors and shareholders. Interest rates ranging from 10% to 19.5%. Please refer Note - 38





Notes forming part of the Financial Statements for the year Ended 31 March 2024

(Amount in ₹ Lakhs)

## 6 Provisions

	Long	term	Short te	rm -
	31-Mar-2024	31-Mar-2023	31-Mar-2024	31-Mar-2023
Provision for Leave Encashment	11.48	7.61	1.57	1.02
Provision for Gratuity	32.65	0.14	0.56	19.60
Provision for Income tax [net of advance tax of Rs. (previous year Nil)]	-	-	-	-
Total	44.14	7.75	2.13	20.62

7 Other Non-current liabilities	31-Mar-24	31-Mar-23
Trade Payables: Retention money Payable	48.76	49.26
	48.76	49.26
8 Short-term borrowings		
Secured -Term loans Working Capital Loans Repayable on Demand from Banks **	204.40	400.70
Current Maturities on Long Term Borrowings	384.19 707.06	193.73 599.43
Short-Term Maturities of Finance Lease Obligation	398.93	376.94
	1,490.18	1,170.10

<sup>\*\*</sup> Pari-passu charge by way of hypothecation of all stocksnad bookdets and other current assets of hospital. ROI for Union Bank of India is EBLR (6.80%) + 4.25% - 0.25% = 10.80% ROI for Bank of Maharastra is EBLR (6.90%) + 3.00% + 0.50% = 10.40%

## 9 Trade payables

<ul> <li>(a) Total outstanding dues of micro enterprises and small enterprises*</li> <li>(b) Total outstanding dues of creditors other than micro</li> </ul>	120.47	110.39
enterprises and small enterprises*	926.44	781.92
	1,046.91	892.31

<sup>\*</sup> Refer Note No 29

<sup>\*</sup>Ageing of Trade payables for FY 2023-24

	Outstandin	g for following	periods from du	e date of payment	
Particulars	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
(i) MSME	96.08	18.51	5,35	0.54	120.47
(ii) Others	537.41	337.47	17.20	34.36	926.44
(iii) Disputed dues— MSME	-	-	-	-	-
(iv) Disputed dues— Others	-	=	-	-	-



C Square Healthcare Private Limited Notes forming part of the Financial Statements for the year Ended 31 March 2024 (Amount in ₹ Lakhs)

\*Ageing of Trade payables for FY 2022-23

	Outstandin	g for following	periods from du	e date of payment	
Particulars	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
(i) MSME	104.51	5.35	0.49	0.05	110.39
(ii) Others	730.35	17.20	12.07	22.29	781.92
(iii) Disputed dues— MSME	-	:=:	-	-	-
(iv) Disputed dues— Others	-	-		-	-

10 Other current liabilities	31-Mar-2024	31-Mar-2023
Interest accrued but not due on borrowings	9.41	28.01
Accrued expenses	215.38	118.36
Dues to employees	203.07	143.58
Duties and taxes payable	187.72	139.52
GST Payable	£	1.70
	615.58	431.17





Notes forming part of Financial Statements

Note 11 - Property, Plant and Equipment (and Intangible Assets)

(Amount in ₹ Lakhs)

		Gross Block	Block			Depreciation		Net Block	lock
Assets	As at 01-04-2023	Additions for the Year	Deletions for the Year	As at 31-03-2024	As at 01-04-2023	For the Year	As at 31-03-2024	As at 31-03-2024	As at 31-03-2023
(A) Tangible Assets									
Computers & Peripherals	28.74	18	<b>L</b> p	28.74	21.14	4.52	25.66	3.08	7.60
Furniture & Fixtures	226.43	13.46	1	239.89	133.88	25.72	159.61	80.28	92.55
Lease Hold Hospital Building	3,609.05	7.47	1	3,616.52	261.17	115.60	376.77	3,239.75	3,347.87
Building on Finance Lease	3,307.04	ř		3,307.04	725.71	110.23	835.95	2,471.10	2,581.33
Medical Equipments	1,015.81	38.55	,	1,054.37	515.91	108.83	624.74	429.63	499.90
Medical Instruments	46.66	21.22	,	67.88	24.16	7.19	31.36	36.52	22.49
Office Equipment	69.82	5.70		75.52	80.09	5.56	65.64	9.88	9.74
Plant & Equipments	692.09	5.77	5 -	700.86	466.88	60.25	527.12	173.73	228.21
Vehicle	14.06	Ĭ	ı	14.06	4.76	2.91	7.67	6.38	9.30
Subtotal	9,012.69	92.18		9,104.88	2,213.71	440.81	2,654.51	6,450.36	6,798.99
(B) Intangible Assets									
Computer software	13.30	3.	1	13.30	9.76	1.18	10.94	2.36	3.55
Servers	16.61	ı		16.61	11.61	0.84	12.45	4.16	2.00
Licenses	9.77	č	E	9.77	8.14	0.16	8.31	1.47	1.63
Subtotal	39.68	•		39.68	29.51	2.18	31.69	7.99	10.18
Grand Total	9,052.37	92.18		9,144.56	2,243.22	442.99	2,686.20	6,458.35	6,809.17
									The same of the sa





C Square Healthcare Private Limited

Notes forming part of Financial Statements

Note 11 - Property, Plant and Equipment (and Intangible Assets)

(Amount in ₹ Lakhs)

		Gross Block	Block			Depreciation		Net Block	lock
Assets	As at 01-04-2022	Additions for the Year	Deletions for the Year	As at 31-03-2023	As at 01-04-2023	For the Year	As at 31-03-2023	As at 31-03-2023	As at 31-03-2022
(A) Tangible Assets									
Computers & Peripherals (4)	20.62	8.12		28.74	12.56	8.58	21.14	7.60	9.24
Furniture & Fixtures (4)	220.62	5.81	ï	226.43	102.15	31.73	133.88	92.55	119.54
Lease Hold Hospital Building (5)	3,602.92	6.13	ı	3,609.05	145.83	115.35	261.18	3,347.87	3,681.07
Building on Finance Lease (6)	3,307.04	0	•	3,307.04	615.48	110.23	725.71	2,581.33	1
Medical Equipments (4)	956.27	59.54	1	1,015.81	391.38	124.53	515.91	499.90	576.93
Medical Instruments	46.44	0.22	1	46.66	18.36	5.81	24.17	22.49	28.08
Office Equipment	69.07	0.75	į	69.82	52.26	7.82	80.09	9.74	16.81
Plant & Equipments	668.88	26.21	•	692.09	393.57	73.31	466.88	228.21	275.31
Vehicle	13.13	0.93	ľ	14.06	0.61	4.15	4.76	9.30	12.52
Subtotal	8,904.99	107.71	•	9,012.69	1,732.19	481.51	2,213.72	6,798.99	4,719.50
(B) Intangible Assets									
Computer software	11.00	2.30		13.30	5.84	3.91	9.75	3.55	5.15
Servers	16.61	r	(E)	16.61	8.84	2.77	11.61	5.00	7.77
Licenses	9.77	ř	· ·	9.77	7.49	0.65	8.14	1.63	2.28
Subtotal	37.38	2.30		39.68	22.17	7.33	29.50	10.18	15.20
Grand Total	8,942.37	110.01	1	9,052.37	1,754.37	488.84	2,243.22	6,809.17	4,734.70





Notes forming part of Financial Statements

Note 12 - Capital Work in Progress

Assets	As at	As at
apital Work in Progress	10010010	272-00-10
Opening Balace	233.60	
Additions during the year*		233.60
Closing Balance	233.60	233.60

## \* CWIP Ageging: -

CWIP as on 31st March 2024 pertains to assets purchased during the FY 17-18 and transferred to CWIP during the previous year.





			(Ar	nount in ₹ Lakhs)
13	Long-term loans and advances		31-Mar-2024	31-Mar-2023
	Loans and advances to related parties	_	-	-
	Other loans and advances			
	Secured, considered good		-	₽
	Unsecured, considered good		-	=
	Doubtful		-	-
	Security Deposits	_	265.73	263.72
		=	265.73	263.72
14	Inventories			
	Valued at lower of cost and net realisable value			
	Medical consumables, drugs and others		98.80	105.02
		-	98.80	105.02
15	Trade receivables	=		<del></del>
	Outstanding for a period more than six months from the date they are due for payment			
	Secured, considered good			-
	Unsecured, considered good		=	15.41
	Unsecured, considered doubtful		33.91	12.02
		-	33.91	27.43
	Less: Provision for doubtful receivables		(33.91)	(12.02)
	¥	(A)	•	15.41
	Others	_		ä
	Secured, considered good		<del>-</del>	
	Unsecured, considered good		86.21	94.47
	Unsecured, considered doubtful		39.74	19
	5.	-	125.96	94.47
	Less: Provision for doubtful receivables		(39.74)	-
		(B) _	86.21	94.47
		(A + B)	86.21	109.88

## \*Ageing of Trade receivables for FY 2023-24

	Outsta	anding for fo	llowing period	ds from due date of	payment
Particulars	Less than 1	1-2 years	2-3 years	More than 3 years	Total
(i) MSME	-	20	_	-	-
(ii) Others	52.31	33.91		-	86.21
(iii) Disputed dues— MSME	-	-	-	<u>-</u>	-
(iv) Disputed dues— Others	-	-	-	-	

## \*Ageing of Trade receivables for FY 2022-23

34	Outsta	inding for fol	lowing period	ds from due date of	payment
Particulars	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
(i) MSME	-	-	-	-	=
(ii) Others	109.35	0.53	-	-	109.88
(iii) Disputed dues- MSME	-	=	-	-	
(iv) Disputed dues— Others	-	-	-	-	-





(Amount in ₹ Lakhs)

16 Cash and bank balances	31-Mar-2024	31-Mar-2023
Cash and cash equivalents		
Cash on hand	6.12	2.87
Bank balances		
In current accounts	7.67	13.75
In demand deposits (less than 3 months maturity)	-	-
Other bank balances		
Deposits held as secutiry against borrowings (Refer Note 5)	6.46	262.73
	20.25	279.35
17 Short term loans and advances		
(Unsecured, considered good, unless stated otherwise)		
Advance to Suppliers	93.84	67.93
Balances with Government	262.17	358.44
	356.01	426.37
18 Other current assets		
Prepaid expenses	14.35	11.78
Interest Receivable	1.53	4.49
Unbilled Revenue	16.29	52.96
	32.17	69.23





19 Revenue from operations	31-Mar-2024	mount in ₹ Lakhs) 31-Mar-2023
(a) Sale of services		
Healthcare services		
Operating income - In patients department	3,967.11	3,573.61
Operating income - Out patients department	919.29	765.44
Income from clinical/ laboratories services	663.45	364.81
Less: Discount	(523.54)	(413.12)
(b) Sale of products - Trading		
Pharmacy	281.45	235.04
Less: Discount	(19.24)	(14.21)
	5,288.52	4,511.56
20 Other Income		
Interest income	10.10	13.77
Other non-operating income		
Miscellaneous income	23.19	16.41
	33.29	30.19
21 Purchase of medical consumable and drugs		
Purchases of material	911.17	825.54
	911.17	825.54
22 Changes in inventories of finished goods, work-in- progress and Stock-in-Trade		
Opening Stock Finished goods	105.02	131.17
Less:		-
Closing Stock Finished goods	(98.80)	(105.02)
(Increase)/Decrease	6.22	26.15
23 Employee benefits expense		
Salaries, wages, bonus and other allowances	960.67	826.71
Staff welfare expenses	9.91	5.14
Contribution to provident and other funds	51.59	53.04
Insurance to Employees		10.85
Gratuity expenses	13.48	-
Leace Encashment Expense	4.43	8.62
24 Finance cost	1,040.08	904.36
(a) Interest expense on		
Term loans	207.07	193.47
Cash Credits	38.29	18.62
MSME Loans	61.33	73.89
Others Loans	130.38	194.54
(b) Other borrowing cost	11.88	16.67
(c) Interest on Finance Lease	508.79	492.19
	957.74	989.38



## (Amount in ₹ Lakhs)

		Α)	mount in ₹ Lakhs)
25	Depreciation and amortization expense		
	On tangible assets (Refer note 12)	440.81	481.51
	On intangible assets (Refer note 12)	2.18	7.33
		442.99	488.84
			mount in ₹ Lakhs)
26	Other Expenses	31-Mar-2024	31-Mar-2023
	Ambulance Charges	5.93	6.62
	Audit Fees	3.50	2.30
	Bank Charges	18.00	18.42
	Communication	12.36	9.14
	Courier Charges	2.26	1.50
	Doctors' Consultant Fee	1,211.50	1,114.72
	Fund Raising Expenses	-	4.15
	Hospital Maintanence Charges	12.95	9.77
	Insurance Expenses	1.96	0.72
	Lab Consumables and Charges	100.64	73.59
	Legal and Professional fee	309.07	236.62
	Licensing Fees	2.62	0.54
	Marketing and Business Promotion Expense	84.50	46.01
	Miscellaneous expenses	5.95	2.73
	Office Expenses	2.96	5.21
	Other contract cost	76.36	57.67
	Patient Expendiure	103.40	76.57
	Power Utility charges	147.18	124.25
	Printing & Stationary Expense	35.13	18.81
	Property Tax for Leasehold Hospital Building	7.69	7.06
	Provision For Bad and Doubtful Debts	73.65	12.02
	Provision For Doubtful Assets (GST Input)	-	69.08
	Rates & Taxes	27.49	135,92
	Rent	7.20	6.83
	Rent of Equipments	20.45	12.18
	Repairs & Maintenance		
	Buildings	37.32	33.15
	Plant and Machinary	27.10	20.20
	Others	27.04	10.67
	Royalty	180.83	79.52
	Security Service Charges	42.15	33.83
	Staff Recruitment Charges	0.03	0.86
	Travelling & Conveyance	1.37	2.47





2,233.11

2,588.59

Notes forming part of the Financial Statements

(Amount in ₹ Lakhs)

245.86

Note: The following is the break-up of Auditors remuneration (exclusive of GST)

	31-Mar-2024	31-Mar-2023
As auditor:		
Statutory audit	3.50	2.30
Tax audit	0.75	-
Other services (Specify nature)	. <del></del>	-
Reimbursement of expenses	W	
Total	4.25	2.30
	(A	amount in ₹ Lakhs)
	31-Mar-2024	31-Mar-2023
27 Exceptional Items		
Bad Debts*	-	248.48
Provisions No Longer Required Written Back	-	(2.62)
	* · · · · · · · · · · · · · · · · · · ·	

The management during the year ended 31 March 2023 has undertaken a comprehensive review of its Trade receivables, including verifying underlying supporting documents, obtaining confirmations and reconciling on-account payments with party wise receivables. Based on such review, the management has identified trade receivables amounting to Rs. 2,48,47,410 (Rupees Two Crore Forty Eight Lakhs Forty Seven Thousasnd Four Hundred and Ten only) as receivables where recoverability is significantly doubtful. These receivables are all aged over 360 days due as on 31 March 2023 and are written off.

## 28 Prior Period Items

		1,582.66
Adjustment of Prior year depreciation #	•	4.68
Reversal of Rental Expense booked till previous years	÷	(1,493.77)
Depreciation on adoption of Finance Lease ##	<b>1</b>	615.48
Interest expense on adoption of Finance Lease ##		2,456.27

## # Please refer Note 12

##

Classification of lease - The Company has on 1 September 2016 entered into a lease arragement for the premises (land and building) on which it currently operates. The same was erroneously classified as operating lease during the previous financial years starting with financial year 2016-17 upto financial year ended on 31 March 2022. The monthly rental charges were charged as Rent expense in the Profit and Loss account during this period. Further, the rental expense was not straight lined and the audit report for the year ended 31 March 2022 was modified on account of this.

The Management, based on the rights, obligations and other conditions of the said lease arragement, has determined the classification of such lease to be Finance lease in accordance with AS 19 - Leases. Such change in classification has been applied retrospectively in accordance with AS 5 - Net Profit or Loss for the Period, Prior Period Items and Changes in Accounting Policies. Accordingly, Interest on Finance Lease Obligations and Depreciation on Assets under Finance Lease have been charged for prior periods (upto 31 March 2022) and the rental expense charged to the Profit and Loss Account of prior periods (upto 31 March 2022) has been reversed. The impact of the aforesaid items on the such change in classification has been reported seperately under Note 27 - Prior Period Items. The net impact of such Prior period items on the Profit and Loss Account for the year ended 31 March 2023 amounted to Rs. 15,77,98,420 (Rupees Fifteen Crore Seventy Seven Lakhs Nintey Eight Thousand Found Hundred and Twenty Only.)

Notes forming part of the financial statements

## 29 Disclosures required under Section 22 of the Micro, Small and Medium Enterprises Development Act,

a) Dues to Micro Enterprises and Small Enterprises to whom the Company owes any sum, comprises of the following:

(Amount in ₹ Lakhs)

Particulars	As at 31 March, 2024	As at 31 March, 2023
(i) Principal amount remaining unpaid to any supplier as at the end of the accounting year	24.39	49.23
(ii) Interest due thereon remaining unpaid to any supplier as at the end of the accounting year	-	<b>⊢</b> rox
(iii) The amount of interest paid along with the amounts of the payment made to the supplier beyond the appointed day	-	н
(iv) The amount of interest due and payable for the year	-	-
(v) The amount of interest accrued and remaining unpaid at the end of the accounting year	1.52	6.77
(vi) The amount of further interest due and payable even in the succeeding year, until such date when the interest dues as above are actually paid	<u>-</u>	-

- 30 a) There are no outstanding forward contracts entered into by the Company.
  - b) There are no outstanding foreign currency exposure as at year end that has not been hedged by derivative instrument or otherwise.

## 31 Expenditure in foreign currency:

Particulars	For the year ended 31 March, 2024	For the year ended 31 March, 2023	
Healthcare Services	₩.		

## 32 Earnings in foreign currency:

Particulars	For the year ended 31 March, 2024	For the year ended 31 March, 2023	
Income from Healthcare Services	-	-	





Notes forming part of the financial statements

## 33 Employee benefit plans:

## a) Defined contribution plans:

The Company makes Provident Fund and Employee State Insurance Scheme contributions which are defined contribution plans, for qualifying employees. Under the Schemes, the Company is required to contribute a specified percentage of the payroll costs to fund the benefits. The Company recognised ₹51,58,672 (Year ended 31 March, 2023 - ₹53,03,840) for Provident Fund contributions, ₹8,25,870 (Year ended 31 March, 2023 - ₹9,75,836) for Employee State Insurance Scheme contributions in the Statement of Profit and Loss. The contributions payable to these plans by the Company are at rates specified in the rules of the schemes.

## b) Defined benefit plan

## Gratuity

In accordance with Accounting Standard 15, an actuarial valuation was carried out in respect of the aforesaid defined benefit plan based on the following assumptions.

## i. Actuarial assumptions

Particulars	31 March 2024	31-Mar-23
Discount rate (per annum)	7.22%	7.52%
Expected Rate of increase in compensation levels	0%	0%
Mortality Rate	(% of IALM 12-14)	(% of IALM 12- 14)
Retirement age	60 years	60 years
Attrition Rate	5%	5%

## ii. Defined benefit obligation (DBO) liability statement

## (Amount in ₹ Lakhs)

Particulars	31 March 2024	31-Mar-23		
Present value obligation as at the beginning of the year	19.73	22.24		
Interest cost	1.48	1.68		
Current service cost	11.97	7.45		
Benefits paid	y <del>-</del>	.=.		
Actuarial loss/ (gain) due to change in assumptions	-	-		
Actuarial loss/(gain) due to plan experience	0.03	(11.63)		
Present value obligation as at the end of the year	33.21	19.73		

## iii. Expenses recognized in Statement of profit and loss

Particulars	31 March 2024	31-Mar-23
Current service cost (including risk premium for fully insured benefits)	11.97	7.45
Interest cost on DBO	1.48	1.68
Immediate Recognition of (Gain)/Losses	0.03	(11.63)
Total expense recognised in Statement of profit and loss.	13.48	(2.50)





Notes forming part of the financial statements

## 34 Capital Commitments

(Amount in ₹ Lakhs)

Particualrs	31 March 2024	<b>31-Mar-23</b> 189.13	
Contingent liabilities	189.13		
Capital Commitments	40.00	40.00	

## 35 Earning per share

Description	For the year ended 31 March, 2024	For the year ended 31 March, 2023	
Net profit/ (loss) after tax available for equity shares (A)	(624.98)	(2,542.71)	
Weighted average number of equity shares of 10 paise each (B)	22.41	22.41	
Basic and Diluted earnings/(Loss) per share in ('₹) (A/B)	(27.89)	(113.46)	

## 36 Deferred tax asset

As at March 31, 2024, the Company has a net deferred tax asset, which has not been recognized based on the management's estimates of future taxable profits and as a matter of prudence.

## 37 Segment Reporting

As the Entity's business activity falls within a single primary business segment, viz. providing "Healthcare Services", the disclosure requirements of Accounting Standard - 17 "Segment Reporting" is not applicable. Entity has no geographical segment as all services are provided in one geographical region.

## 38 Related party disclosures:

a) Name of related parties and description of relationship:

Description of relationship	Name of the Party			
Key Managerial Personnel and Director	a) Dr. Kudingila Radha Madhava b) Dr. Ramachandra Prakash Bharathura c) Dr. Srinivas Chirukuri d) Dr. Mangerira Chinnappa Uthappa e) Dr. Somnath Chatterjee			
Relative to KMP	a) Dr. T.R. Sreelakshmi - Spouse of Dr. Kudingila Radha Madhava - Director     b) Dr. Sai Lakshmi - Spouse of Dr. Somnath Chatterjee - Director			





Notes forming part of the financial statements

b) Details of transactions during the year and year end balances are as below:

(Amount in ₹ Lakhs)

(Amount in ₹ La				
Description	Key Managerial Personnel and Directors		Relatives of Key Managerial Personnel	
	23-24	22-23	23-24	22-23
1. Transactions during the year				
a. Salary, Director Remuneration,				
Bonus, Professional Fee, Consultant	1			
Fee etc	2000 COV			
Dr. Kudingila Radha Madhava	12.60	59.33	-	-
Dr. Ramachandra Prakash Bharathura	25.20	28.40	-	
Dr. Srinivas Chirukuri	75.60	75.38	-	-
Dr. Mangerira Chinnappa Uthappa	12.60	15.41	-	-
Dr. Somnath Chatterjee	69.30	66.00	-	-
Dr. Arvind A S	9.60	₩.	=	-
Dr. Sai Lakshmi	3.87	-		
b. Loans Received				
Dr.Ashith Kumar Shetty	_	9.50	_	_
Dr. Sreelakshmi T R		-	_	20,00
c. Principle repayment				20.00
Dr. Kudingila Radha Madhava	36.98	31.60	_	
Dr. Ramachandra Prakash Bharathura	10.96	26.71	_	_
Dr. Srinivas Chirukuri	19.70	30.27	-	-
Dr. Mangerira Chinnappa Uthappa	16.08	35.82	-	_
Dr. Somanath Chatterjee	28.43	22.05	-	-
Dr. Arvind A S		22.05	-	-
Dr. Sreelakshmi T R	75.00 20.00	-	-	-
Dr.Ashith Kumar Shetty	9.50	-	-	J=
d. Interest payment	9.50	5	· =	, -
ADM ASSIST WAS TO ASSIST WAS MADE WAS ASSISTED ASSISTANCE.	4.70	0.00		
Dr. Kudingila Radha Madhava Dr. Ramachandra Prakash Bharathura	4.70	9.09	-	~
Dr. Srinivas Chirukuri	0.96	4.20	~	-
	1.56	5.50	-	-
Dr. Mangerira Chinnappa Uthappa	1.56	6.11	-	-
Dr. Somanath Chatterjee	10.68	12.06	-	-
Dr. Arvind A S	0.76	-	-	-
Dr. Sreelakshmi T R	0.25	-	-	
2. Balances outstanding at the end of the year				
Loan payable and Interest payable				
Dr. Kudingila Radha Madhava	8.14	45.12		TD NOT
Dr. Ramachandra Prakash Bharathura	0.43	10.54	-	
Dr. Srinivas Chirukuri	5.22	24.92		-
Dr. Mangerira Chinnappa Uthappa	3.22	16.30	-	_
Dr. Somanath Chatterjee	45.47	73.90		-
Dr. Arvind A S	45.47	550.00	-	_
DI. AIVING A O	4/5.00	550.00	-	-
		1	Lancard Company	

## Notes:

1) Related party relationship is as identified by the management and relied upon by the Auditors.

2) No amount is/has been written off or written back during the year in respect of debts due from or to related party.

Notes forming part of the financial statements

## 39 Ratios

The ratios for the years ended March 31, 2024 and March 31, 2023 are as follows :

Particulars	Numerator	Denominator	As at 31-03-2024	As at 31-03-2023	Variance in(%)	Reason for Variance
Current ratio (in times)	Total Current Assets	Total Current Liabilities	0.19	0.39	-0.52	
Debt-equity ratio (in times)	Total Debt including lease liabilities	Total Equity	(3.65)	-6.72	-0.46	
Debt service coverage ratio (in times)	Net Profit after taxes + Non- cash operating expenses + Interest expenses + other non cash adjustments+ Exceptional Items	Interest expense + principal repayments and lease liabilities payment made during the year	0	0	0%	
Return on equity ratio (in times)	Profit after tax (Attributable to Owners)	Average net worth	0.476	2.077	-77%	Due to prior period adjustments
Trade receivables turnover ratio (in times)	Revenue from operations	Average Trade receivables	61.342	41.059	49%	Due to prior period adjustments
Trade payables turnover ratio (in times)	Revenue from operations	Average Trade payables	5.052	5.056	0%	2
Net capital turnover ratio (in times)	Revenue from operations	Average working capital (i.e. Total current assets less Total current liabilities	2.065	2.960	-30%	9
Net profit ratio (in %)	Profit after tax	Revenue from operations	-0.1182	-0.5636	-79%	Due to prior period adjustments
Return on capital employed	Net Profit before interest and taxes	Capital employed = Net worth + Lease liabilities + Deferred tax liabilities	0.338	2.249	-85%	Due to prior period adjustments





Notes forming part of the financial statements

The Company has made purchases with companies struck off under section 248 of the 'Companies Act, 2013 or scetion 560 of the Companies Act, 1956, Summary of transactions is as follows:

(Amount in ₹ Lakhs)

		31-Mar-24		31-Mar-23	
Name of the Struck off Company	Nature of Transaction	Balance Outstanding	Relation	Balance Outstanding	Relation
Accurate Medical Service Private Limited	Payables - Paid Off	-	Supplier	0.31	Supplier
Arihanth Marketing and Tradecom Private Limited	Payables	2.68	Supplier	1.49	Supplier
Bangalore Healthcare Services Private Limited	Payables - Paid Off	s <b>=</b> 8	Supplier	0.64	Supplier
Dia Care Pharmaceuticals Private Limited	Payables - Paid Off	-	Supplier	0.18	Supplier
Hindmed Lab Private Limited	Payables	6.52	Supplier	0.65	Supplier
Krupa Healthcare Private Limited	Payables	0.01	Supplier	0.01	Supplier
Kushal Pharma Private limited	Payables - Paid Off	Ξ.	Supplier	0.10	Supplier
Manjunatha Enterprises Private Limited	Payables - Paid Off	=	Supplier	0.11	Supplier
Orange Computer Services Private Limited	Payables - Paid Off	-	Supplier	0.15	Supplier
Power tools and tackles India Private Limited	Payables	0.10	Supplier	0.10	Supplier
Raja Enterprises Private Limited	Payables	0.04	Supplier	0.04	Supplier
Sky Marketing Private Limited	Payables - Paid Off		Supplier	2.99	Supplier
Labelkraft Technologies Ltd (Earlier Solanki Enterprises)	Payables - Paid Off	0.04	Supplier	1.09	Supplier
Sristi Digitallmages Private Limited	Payables	6.05	Supplier	4.84	Supplier
Stitch Factory Private Limited	Payables	0.04	Supplier	0.04	Supplier
Tulsi Pharma Private Limited	Payables - Paid Off		Supplier	0.19	Supplier
United Agencies Private Limited	Payables	0.59	Supplier	0.60	Supplier
Varsha Impex Private Limited	Payables - Paid Off	0.14	Supplier	0.14	Supplier
Vimal Pharma Private Limited	Payables - Paid Off		Supplier	0.06	Supplier





Notes forming part of the financial statements

- 41 Previous year's figures have been regrouped / reclassified wherever necessary to correspond with the current year's classification / disclosure.
- As required by the proviso to Rule 3(1) of the Companies (Accounts) Rules,2014 which is applicable from 01 April 2023, the company uses an accounting software for mainting its books of account which has a feature of recording audit trail (edit log) facility. However, the audit trail feature was not enabled by the company throughtout the financial year ended 31st March 2024.

## 43 Additional Regulatory Information Required By Schedule III

- (I) Relationship With Struck Off Companies
  - The Company has transactions with the companies struck off under Companies Act, 2013 or Companies Act, 1956. Refer Note 38 above
- (II) Loans and advances
  - Company has not granted any loans or advances in the nature of loans to promoters, directors, key managerial personnel (KMPs) and the related parties (as defined under Companies Act, 2013) either severally or jointly with any other person.
- (III) Details Of Benami Property Held
  - No proceedings have been initiated on or are pending against the Company under the Prohibition of Benami Property Transactions Act, 1988 (as amended in 2016) (formerly the Benami Transactions (Prohibition) Act, 1988 (45 of 1988)) and Rules made thereunder.
- (IV) Wilful Defaulter
  - The Company has not been declared wilful defaulter by any bank or financial institution or government or any government authority.
- (V) Details Of Crypto Currency Or Virtual Currency. The Company has not traded or invested in crypto currency or virtual currency during the current or previous year.
- (VI) Valuation Of Property Plant And Equipment And Intangible Asset
  - The Company has not revalued its Property, Plant and Equipment (including Right-of-use assets) and Intangible assets during the current or previous year. The Company did not have any Investment Property during the current or previous year.
- (VII) Registration Of Charges Or Satisfaction With Registrar Of Companies
  - There are no charges or satisfaction which are yet to be registered with the Registrar of Companies beyond the statutory period.
- (VIII Compliance With Number Of Layers Of Companies
  - The Company has complied with the number of layers prescribed under Section 2(87) of the Companies Act, 2013 read with Companies (Restriction of number of layers) Rules, 2017.
- (IX) Undisclosed Income
  - There is no income surrendered or disclosed as income during the current or previous year in the tax assessments under the Income Tax Act, 1961, that has not been recorded in the books of account.
- (X) Compliance With Approved Scheme(S) Of Arrangements
  - The Company has not entered into any scheme of arrangement which has an accounting impact on current or previous financial year.
- (XI) Corporate Social Responsibility Expenditure
  - Provisions of Section 135(1) of the Companies Act, 2013 with respect to mandatory Corporate Social Responsibility Expenditure is not applicable to the Company





Notes forming part of the financial statements

(XII) Utilisation of Borrowed funds and share premium

- (A) The Company has not advanced or loaned or invested funds (either borrowed funds or share premium or any other sources or kind of funds) to any other person(s) or entity(ies), including foreign entities ("Intermediaries") with the understanding (whether recorded in writing or otherwise) that the Intermediary shall
- i) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company ("Ultimate Beneficiaries"); or
- ii) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries;
- (B) The Company has not received any fund from any person(s) or entity(ies), including foreign entities ("Funding Party") with the understanding (whether recorded in writing or otherwise) that the company shall
- i) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries); or
- ii) provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

For GVNKA & Assocaites **Chartered Accountants** 

Firm Registration Number: 023904N

For and on behalf of Board of Directors C Square Healthcare Private Limited

CIN: U85191KA2013PTC070244

per Prashanth Vellanki

Partner

Membership Number: 226413

UDIN: 24226413BKGGEK4964

Bengaluru

06-Sep-24

Ramachandra Prakash Bharathura

Managing Director

DIN: 06780998

Bengaluru

06-Sep-24

Director

DIN: 03531032

Srinivas Chirukuri

**Bengaluru** 

m 06-Sep-24

THCAR